REPH - Recro Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.51
-0.12 (-2.13%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.63
Open5.58
Bid5.54 x 900
Ask5.55 x 800
Day's Range5.27 - 5.67
52 Week Range5.27 - 13.05
Volume1,235,210
Avg. Volume275,161
Market Cap112.997M
Beta-0.24
PE Ratio (TTM)N/A
EPS (TTM)-2.86
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.25
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Recro Pharma, Inc. - REPH

    NEW YORK , May 25, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ: REPH).   Such investors ...

  • ACCESSWIRE7 hours ago

    Today’s Research Reports on Stocks to Watch: Recro Pharma and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Recro Pharma shares saw a huge drop and hit a new low after the FDA declined to approve the company's IV meloxicam, which was supposed to be the company's first ...

  • Benzingayesterday

    FDA Declines Recro's IV Meloxicam Application

    Recro Pharma Inc (NASDAQ: REPH) needs an analgesic of its own. IV meloxicam was meant to be Recro’s first marketed product. Despite the roadblock, Recro is not prepared to abandon IV meloxicam just yet.

  • Reutersyesterday

    Recro Pharma shares plummet after FDA rejects non-opioid pain shot

    Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations. It is also a major blow to Recro Pharma, whose IV meloxicam would have been the company's first drug in the market. Recro did not say whether the FDA might require a new study in a conference call.

  • MarketWatchyesterday

    Recro Pharma's stock loses more than half its value after receiving CRL from FDA

    Shares of Recro Pharma Inc. lost more than half their value in premarket trade Thursday, after the pharmaceutical company said it received a complete response letter (CRL) from the Food and Drug Administration regarding its new drug application (NDA) for its non-opioid pain treatment. The CRL says that although phase 3 trials of IV meloxicam met primary endpoints, the FDA said it could not approve the NDA in its current form because data from selective secondary endpoints suggest the analgesic effect does not meet expectations.

  • Reutersyesterday

    FDA declines to approve Recro Pharma's non-opioid pain shot

    The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations. The drug is a non-opioid injection ...

  • GlobeNewswireyesterday

    Recro Pharma Receives Complete Response Letter from the FDA

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding the New Drug Application (NDA) for IV meloxicam. “We are extremely disappointed for patients and providers who are looking for a non-opioid alternative for relief of pain.  We stand behind the body of evidence included in our NDA and are committed to further discussions with FDA in order to bring this important medicine to patients.  We intend to request a meeting with the FDA as soon as possible to discuss the points raised in the CRL and look forward to working with the Agency to find solutions that can contribute to solving the current opioid public healthcare problem,” said Gerri Henwood, President and Chief Executive Officer of Recro.

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of REPH earnings conference call or presentation 9-May-18 12:00pm GMT

    Q1 2018 Recro Pharma Inc Earnings Call

  • Associated Press16 days ago

    Recro Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 65 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire16 days ago

    Recro Pharma Reports First Quarter 2018 Financial Results

    Upcoming May 26, 2018 PDUFA Date for IV Meloxicam. Company to Host Conference Call Today at 8:00 AM ET. MALVERN, Pa., May 09, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company ...

  • GlobeNewswire18 days ago

    Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the receipt of issue notifications for three patents covering intravenous (IV) meloxicam from the U.S. Patent and Trademark Office (USPTO). The patents are exclusively licensed from Alkermes Pharma Ireland Limited. The patents relate to the reduced flake-like aggregates of the injectable nanoparticle meloxicam composition and methods of producing such compositions.

  • GlobeNewswire23 days ago

    Recro Pharma Announces Commercial Team Additions

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for  the hospital and other acute care settings, today announced the expansion of its team through the appointment of two new employees in the area of acute care commercialization. In connection with the hiring of these personnel, the Compensation Committee of Recro Pharma’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 18,250 shares of Recro Pharma’s common stock and restricted stock units covering 2,500 shares of Recro Pharma’s common stock. The equity awards were granted pursuant to the NASDAQ Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Recro Pharma.  The option awards and restricted stock units were granted on April 30, 2018 and the option awards will have an exercise price equal to the closing price of Recro Pharma's common stock on April 30, 2018.

  • GlobeNewswire23 days ago

    Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report first quarter financial results on Wednesday, May 9, 2018. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, May 9, 2018 to discuss the financial results and recent operational highlights. A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, https://ir.recropharma.com/events.

  • GlobeNewswire25 days ago

    Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that a poster highlighting preclinical data for its ultra-short acting neuromuscular blocking (RP2000) and reversal agents was presented at the Association of University Anesthesiologists (AUA) 2018 Annual Meeting, which took place April 26-27, 2018 in Chicago. “This compelling data demonstrates not only the effective and rapid activity of the ultra-short acting neuromuscular blocking agent (NMBA) in a preclinical primate model, but also showcases the ability of the rapid-acting reversal agent to antagonize the molecule and induce recovery,” said John Savarese, Professor Emeritus of Anesthesiology, Weill Cornell Medical College.

  • GlobeNewswirelast month

    Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting

    MALVERN, Pa., April 16, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced eight poster ...

  • GlobeNewswire2 months ago

    Recro Pharma Announces Commercial Team Additions

    MALVERN, Pa., March 29, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the expansion ...

  • ACCESSWIRE2 months ago

    Wired News – Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam

    Stock Monitor: Advaxis Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on Recro Pharma, Inc. (NASDAQ: REPH ). If you want ...

  • GlobeNewswire2 months ago

    Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain

    MALVERN, Pa., March 27, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication ...

  • GlobeNewswire2 months ago

    Recro Pharma to Present at the 17th Annual Needham Healthcare Conference

    MALVERN, Pa., March 21, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...

  • GlobeNewswire3 months ago

    Recro Pharma to Present at Upcoming Investor Conferences

    MALVERN, Pa., March 06, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro ...

  • GlobeNewswire3 months ago

    Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting

    MALVERN, Pa., March 05, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced an Industry‘ ...

  • GuruFocus.com3 months ago

    Recro Pharma Inc (REPH) Files 10-K for the Fiscal Year Ended on December 31, 2017

    Recro Pharma Inc (NASDAQ:REPH) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

  • GlobeNewswire3 months ago

    Recro Pharma Announces Commercial Team Additions

    MALVERN, Pa., March 02, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion ...

  • GlobeNewswire3 months ago

    Recro Pharma Reports Year End 2017 Financial Results

    IV Meloxicam NDA Submitted and PDUFA Action Date Set for May 26, 2018. Record CDMO Performance; 2017 Revenues of $71.8 Million. MALVERN, Pa., Feb. 27, 2018-- Recro Pharma, Inc., a revenue generating specialty ...